Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting ( BROOMFIELD Colo. May 01 2007 /PRNew...)

Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Consistent with the findings of Accera's Phase IIa study, subjects who did not have the ApoE4 genotype-a known genetic risk factor that occurs in half of all AD patients-responded particularly well to treatment, as reflected in statistically significant improvement in AD Assessment Scale- Cognitive (ADAS-Cog) scores.

Subjects underwent pharmacogenomic analysis for a variety of genetic markers and were evaluated through a battery of neuropsychometric tests at Day 0, 45, and 90. Compared to the placebo group, the ADAS-Cog scores of the AC- 1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01), and statistically significant improvement was seen in just 45 days.

Interestingly, ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5 point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease. "The profound effect we see in the population without the ApoE4 risk factor supports the findings of an earlier study linking efficacy to a certain pharmacogenomic profile," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and glucose metabolism."

Regardless of genotype, subjects treated with AC-1202 showed a trend toward improvement (p=.072), suggesting the com
'"/>

Page: 1 2 3
Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:

(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...

(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...

(Date:5/16/2013)... 16, 2013 PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...

Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6 PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2

[0] Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results [0] A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing [0] PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

... 14, 2011 Naviscan, Inc., the worldwide leader in ... Cheng MD, PhD has joined the Naviscan Board of ... business experience related to reimbursement in the medical device ... Affairs and Reimbursement at Acclarent, Inc. After acquisition by ...

... Codexis, Inc. (Nasdaq: CDXS ) today announced the ... Technology Leadership Forum, to be held in Vail, CO on ... Financial Officer, will appear on a panel titled "Crude Alternatives: ... 8 at 12:30 p.m. ET. A webcast is not being ...

Cached Medicine Technology:Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng 2

Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng Codexis to Present at the Pacific Crest and Canaccord Genuity Conferences

(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...

(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...

(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...

(Date:5/18/2013)... 2013 Transvaginal mesh lawsuits ... move forward in a consolidated litigation underway in New ... According to a notice on the Court’s website, the ... litigation will be held on Wednesday, May 22nd. ... in the proceeding on behalf of women who suffered ...

(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...

Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New research identifies practice changes to improve value and quality of GI procedures 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3

[0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New research identifies practice changes to improve value and quality of GI procedures [0] VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities [0] Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation [0] Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets

... the form of percutaneous coronary intervention (PCI) is now ... infarction. New European guidelines issued in November 2008 emphasised ... to restore blood flow to the heart and improve ... in patients with stable coronary artery disease; PCI has ...

... Construction Company, the nation,s leading builder of healthcare facilities, ... proceed with the $42 million Phase Two expansion to ... start in March 2009 with completion scheduled for March ... plant, emergency rooms, ICU, CCU, three operating rooms and ...

... PARK, Ill., Feb. 6 Abbott ( NYSE: ABT ... Antitrust,Improvements Act of 1976 (HSR) applicable to Abbott,s cash ... common stock of Advanced Medical,Optics (AMO) expired last night ... The expiration of the HSR waiting period satisfies ...

... of 7 HIV+ Patients Receiving Dapsone Therapy at Significant ... IRVINE, Calif., Feb. 6 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, today announced that a ... Medicine 38th Critical Care Congress suggests providers should consider ...

... revenues increase by 35% over same period in ... are in Canadian dollars unless otherwise noted),BELLEVILLE, ON, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ... of its 2009 fiscal year, ending December 31, ...

... a new study shows that losing weight is perhaps the ... disorders, according to a new study in the American ... the American Thoracic Society,s three peer-reviewed journals. , Weight ... fancy high-tech treatment, but it is an exciting therapy for ...

Efficacy of stents is improved when their placement is determined by arterial blood flow measurement Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif.Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia Bioniche Reports Fiscal 2009 Second Quarter Losing weight can cure obstructive sleep apnea in overweight patients

... Plate Capability The Equalizer 384 includes ... and equal tip spacing, choice of two software ... addition, this model allows you to evenly space ... accessing many gels and for use with 384 ...

... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...

... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...

Medicine Products:

Impact Equalizer 384 8-Channel Electronic Pipettor, 1-30l Impact2 EXP 8-Channel Electronic Pipettor, 15-1250L Impact EXP 8-Channel Electronic Pipettor, 0.5-12.5L Impact2 EXP 6-Channel Electronic Pipettor, 15-1250L